Additionally, GLP-1 reduces the release of glucagon, another hormone produced by the pancreas, which typically signals the liver to release stored glucose
Studies show that patients who maintain lifestyle changes (reduced calorie intake, regular movement) experience slower weight rebound even after GLP-1 medications leave their system
Clinical trials of FDA-approved semaglutide and tirzepatide show the difference clearly: Semaglutide patients lose about 15% of total body weight Tirzepatide patients lose approximately 21% Both medications can cause mild gastrointestinal side effects, but tirzepatide is often better tolerated, with many patients reporting fewer symptoms
Biomarker screening and genetic predisposition assessment should complementnot replacecomprehensive medical evaluation
Employers arent expanding coverage of GLP-1 obesity drugs many are finding ways around it
More recently, a Because tirzepatide is both a Still, its important to keep in mind that there are limitations to these studies, and more long-term research is needed before determining that one medication is more effective than another
